Here, we have shown that high glucose increased IL-6 and IL-1 expression in breast cancer cells and cardiomyocytes exposed to ipilimumab; notably, also in this case, shifting from high glucose to low glucose and the treatment with empagliflozin reduced significantly IL-6 expression, providing new insight on the putative protective role of low glucose in IL-6 mediated immune-suppression and cardiotoxicity. Here, IL1B is linked to breast carcinoma.